Sheel Biotech Board of Directors

Get the latest insights into the leadership at Sheel Biotech. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Satya Narayan Chandak Chairman & Director
Mr. Divye Chandak Managing Director
Mr. Sanjay Chandak Executive Director
Mr. Mini Chadha Non Executive Director
Mr. Ramesh Chandra Srivastava Non Executive Director
Mr. Shyamsundar Bang Non Executive Director
Mr. Atul Kumar Non Executive Director

Sheel Biotech Share price

SHEEL

00.0

0 (0.00%)
NSE
BSE
Last updated on 8 Oct, 2025 | 02:53 IST
BUYSELL
Today's High

00

Today's Low

00

52 Week Low

00

52 Week High

00

The current prices are delayed, login to your account for live prices

Sheel Biotech FAQs

The board at Sheel Biotech consists of experienced professionals, including Mr. Satya Narayan Chandak , Mr. Divye Chandak , and others, overseeing the company’s strategic and corporate governance.

Directors at Sheel Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Satya Narayan Chandak is the current chairman at Sheel Biotech.

Executive directors at Sheel Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Sheel Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Sheel Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.